In the treatment of intestinal cancer, some studies have concentrated on the combination of TNF inhibitors and immune checkpoint inhibitors (e.g. PD-1/PD-L1 antibodies), given the pro-M2 effect of TNF-α in the tumor microenvironment. This evidence concerns the gene CD274 and neoplasm.